5 Factors That May Affect Multiple Myeloma Outcomes
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Diagnosis & Disease Information
Delirium Tied to Increased Risk of Death in Critically Ill With Cancer
Critically ill patients with cancer who develop delirium have a higher risk of dying in the hospital or intensive care unit, a study suggests.
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Diet Not Associated With Infection Risk in Patients With Neutropenia After HSCT
Randomized noninferiority study compared outcomes for patients with neutropenia after HSCT who followed a protective diet with those who followed a nonrestrictive diet.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Combination Venetoclax Plus Azacitidine Appears Promising in High-Risk MDS or CMML
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Final results from ICARIA-MM support isatuximab plus pomalidomide and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, according to researchers.
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...